Welcome to our dedicated page for Viatris SEC filings (Ticker: VTRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Viatris Inc. filings document the reporting record of a global healthcare company whose common stock trades on Nasdaq under VTRS. Form 8-K disclosures cover operating results, guidance and material events, including leadership transitions, restructuring actions from an enterprise-wide strategic review, bylaw amendments and shareholder-meeting matters.
Proxy statements describe board oversight, executive compensation, shareholder voting proposals, director nominations and governance practices. The filings also provide formal records for Viatris' capital return activity, strategic priorities, pipeline and product references, and the company's history as the combination of Mylan with Pfizer's Upjohn business.
Viatris Inc. completed a public offering of €650,000,000 aggregate principal amount of 4.250% senior unsecured notes due June 17, 2033, guaranteed by Mylan Inc., Mylan II B.V. and Utah Acquisition Sub Inc. The notes were issued under an existing shelf registration.
The company intends to use the net proceeds mainly to repay amounts borrowed under its revolving credit facility that funded the repayment at maturity of $1.675 billion of 3.950% senior notes due 2026, with any remainder to replenish cash for general corporate purposes. The notes pay 4.250% interest annually starting June 17, 2027, include optional redemption before and after an April 17, 2033 par call date, and require a 101% repurchase offer upon certain change of control events.
Viatris Inc. entered into an underwriting agreement to issue and sell €650,000,000 principal amount of 4.250% Senior Notes due 2033. The notes will be offered under an effective shelf registration on Form S-3, using a prospectus dated May 8, 2025 and a prospectus supplement dated June 12, 2026.
The offering is expected to close on June 17, 2026, subject to customary closing conditions. BNP Paribas, Citigroup Global Markets Limited and Goldman Sachs & Co. LLC are acting as representatives of the underwriters. The agreement includes customary representations, warranties and termination provisions.
Viatris Inc. is offering €650,000,000 of 4.250% Senior Notes due June 17, 2033. Interest is payable annually on June 17 beginning June 17, 2027. The notes are senior unsecured and initially guaranteed by Mylan Inc., Mylan II B.V. and Utah Acquisition Sub Inc.
Net proceeds are estimated at approximately €644.0 million and are intended to fund repayment of borrowings used to redeem the $1.675 billion 2026 Senior Notes and to replenish cash for general corporate purposes. The offering will settle on or about June 17, 2026 and listing on Euronext Dublin has been applied for.
Viatris Inc. reported the results of its 2026 annual shareholder meeting, where three proposals were considered. Shareholders elected thirteen director nominees to serve until the 2027 annual meeting, with each nominee receiving a clear majority of votes cast in favor.
Shareholders also approved, on a non-binding advisory basis, the 2025 compensation of the company’s named executive officers, with 846,370,157 votes for, 26,920,688 against, and 2,266,069 abstentions, plus 122,461,640 broker non-votes. They further ratified the selection of Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2026, with 969,259,214 votes for, 27,657,863 against, and 1,101,477 abstentions.
Viatris Inc. reported a return to profitability for the quarter ended March 31, 2026. Total revenues rose to $3.52 billion from $3.25 billion a year earlier, driven by higher net sales across Developed Markets and Greater China. Net earnings reached $176.4 million, compared with a prior-year net loss of $3.04 billion that was heavily affected by goodwill impairment.
Basic and diluted earnings per share were $0.15 versus a loss of $2.55 per share in the prior-year period. Operating cash flow was $388.3 million, and cash and cash equivalents increased to $1.80 billion while long-term debt remained around $12.4 billion. The company maintained a quarterly dividend of $0.12 per share.
Viatris launched a major restructuring program following its enterprise-wide strategic review, targeting a workforce reduction of up to 10% and expecting total pre-tax charges of $700–$850 million over roughly three years; it recorded $77.9 million of related charges this quarter. A fire at its Nashik, India facility led to $71.9 million in charges and a temporary production halt, with full operations expected to resume in July 2026. The company also closed the sale of its Biocon Biologics convertible preferred stake for $400 million in cash plus $415 million in Biocon equity shares.
Viatris Inc. reported a return to profitability for the quarter ended March 31, 2026. Total revenues rose to $3.52 billion from $3.25 billion a year earlier, driven by higher net sales across Developed Markets and Greater China. Net earnings reached $176.4 million, compared with a prior-year net loss of $3.04 billion that was heavily affected by goodwill impairment.
Basic and diluted earnings per share were $0.15 versus a loss of $2.55 per share in the prior-year period. Operating cash flow was $388.3 million, and cash and cash equivalents increased to $1.80 billion while long-term debt remained around $12.4 billion. The company maintained a quarterly dividend of $0.12 per share.
Viatris launched a major restructuring program following its enterprise-wide strategic review, targeting a workforce reduction of up to 10% and expecting total pre-tax charges of $700–$850 million over roughly three years; it recorded $77.9 million of related charges this quarter. A fire at its Nashik, India facility led to $71.9 million in charges and a temporary production halt, with full operations expected to resume in July 2026. The company also closed the sale of its Biocon Biologics convertible preferred stake for $400 million in cash plus $415 million in Biocon equity shares.
Viatris Inc. reported stronger first-quarter 2026 results, with clear growth on a non-GAAP basis and reaffirmed full-year guidance. Total revenues were $3.5 billion, up 8% reported and 3% operationally versus first-quarter 2025, driven largely by Greater China. Adjusted EBITDA reached $1.0 billion, up 14%, while adjusted EPS rose to $0.59, up 18%. U.S. GAAP net earnings were $176 million, compared with a $3.0 billion loss a year earlier that included a large goodwill impairment. Operating cash flow was $388 million and free cash flow $348 million, both below last year, though free cash flow excluding transaction- and restructuring-related costs was $459 million. Management reaffirmed 2026 guidance, including total revenues of $14.45–$14.95 billion, adjusted EBITDA of $4.15–$4.45 billion, adjusted EPS of $2.33–$2.47, and free cash flow excluding transaction- and restructuring-related costs of $1.95–$2.35 billion.
Viatris Inc. reported stronger first-quarter 2026 results, with clear growth on a non-GAAP basis and reaffirmed full-year guidance. Total revenues were $3.5 billion, up 8% reported and 3% operationally versus first-quarter 2025, driven largely by Greater China. Adjusted EBITDA reached $1.0 billion, up 14%, while adjusted EPS rose to $0.59, up 18%. U.S. GAAP net earnings were $176 million, compared with a $3.0 billion loss a year earlier that included a large goodwill impairment. Operating cash flow was $388 million and free cash flow $348 million, both below last year, though free cash flow excluding transaction- and restructuring-related costs was $459 million. Management reaffirmed 2026 guidance, including total revenues of $14.45–$14.95 billion, adjusted EBITDA of $4.15–$4.45 billion, adjusted EPS of $2.33–$2.47, and free cash flow excluding transaction- and restructuring-related costs of $1.95–$2.35 billion.
Davis Selected Advisers files Amendment No. 7 to a Schedule 13G/A reporting 78,211,191 shares of Viatris Inc. common stock, representing 6.8% of the class as disclosed. The filing shows sole voting power for 75,605,333 shares and sole dispositive power for 78,211,191 shares; the ownership figures are tied to the reporting period 03/31/2026.
Viatris Inc. announced a planned Chief Financial Officer transition. Theodora “Doretta” Mistras will step down as CFO effective May 8, 2026, remaining employed until May 22, 2026 to support the handover, and her departure is stated as unrelated to any disagreements over accounting, financial reporting, internal controls or operations.
The Board appointed Paul Campbell, the current Chief Accounting Officer and Corporate Controller, as interim CFO effective May 8, 2026 while it searches for a permanent successor. Mistras will receive a pro rata 2026 bonus based on actual performance (capped at target) but no severance or equity vesting, and must sign a release and comply with restrictive covenants. Viatris also reiterated that it will release first‑quarter 2026 results on May 7, 2026 and hold a conference call at 8:30 a.m. ET.
Viatris Inc reports institutional ownership disclosure: Vanguard Capital Management filed a Schedule 13G reporting beneficial ownership of 84,807,083 shares of Viatris common stock, representing 7.36% of the class as of 03/31/2026. The filing shows sole dispositive power over 84,807,083 shares and sole voting power over 10,090,452 shares. The filing states these holdings reflect securities managed across Vanguard affiliates and funds. Signature on the form is dated 04/30/2026.